PROTEIN MODIFYING ENZYME

Abstract: The present invention relates, in general, to a protein prenyltransferase and, in particular, to protein geranylgeranyltransferase (GGTase-I) and to a nucleic acid sequence encoding same. The invention also relates to methods of producing GGTase-I and geranylgeranyl modified polypeptides. The invention further relates to a method of screening compounds for the ability to alter GGTase-I activity.

Description: PROTEIN MODIFYING ENZYME This invention was made, at least in part, with support from the National Science Foundation (Grant No. DCB9105822) and the National Institutes of Health (Grant No. ROl GM46372) . The Government has certain rights in the invention. TECHNICAL FIELD The present invention relates, in general, to a protein prenyltransferase and, in particular, to protein geranylgeranyltransferase type I (GGTase-I) and to a nucleic acid sequence encoding same. The invention also relates to methods of producing GGTase-I and geranylgeranyl modified polypeptides. The invention further relates to methods of screening compounds for the ability to alter GGTase-I activity. BACKGROUND Covalent modification by isoprenoid lipids (prenylation) contributes to membrane interactions and biological activities of a rapidly expanding group of proteins (Maltese, FASEB J. 4:3319 (1990) ; Glomset et al, Trends Biochem. Sci. 15:139 (1990)) . Either farnesyl (15-carbon) or geranylgeranyl (20-carbon) isoprenoids can be attached to specific proteins, with geranylgeranyl being the predominant isoprenoid found on proteins (Farnsworth et al, Science 247:320 (1990)) . The prenyltransferase, protein geranylgeranyltransferase type-I (GGTase-I) , transfers a geranylgeranyl group from the prenyl donor geranylgeranyl diphosphate to the cysteine residue of substrate proteins containing a C-terminal CAAX-motif in which "A" is any amino acid, including an aliphatic amino acid, and the "X" residue is leucine (Clarke, Ann. Rev. Biochem. 61:355 (1992); Casey, J. Lipid. Res. 330:1731 (1992)) . Known targets of GGTase-I include γ-subunits of brain heterotrimeric G proteins and Ras-related small GTP-binding proteins such as Racl, Rac2, RaplA and RaplB (Menard et al, Eur. J. Biochem. 206:537 (1992) ; Casey et al, Proc. Natl . Acad. Sci. USA 88:8631 (1991) ; Moores et al, J. Biol. Chem. 136:14603 (1991)) . Additionally, short peptides encompassing the CAAX motif of these substrates can also be recognized by the enzyme (Casey et al, Proc. Natl. Acad. Sci. USA 88:8631 (1991); (Moores et al, J. Biol. Chem. 136:14603 (1991); Yokoyama et al, Proc. Natl. Acad. Sci. USA 88:5302 (1991)) . Immobilization of one such peptide for use as an affinity matrix has led to the isolation of GGTase-I from bovine brain (Moomaw and Casey, J. Biol. Chem. 267:17438 (1992)) . The purified enzyme contains two subunits with molecular masses of 48 kDa and 43 kDa, which have been designated, respectively, as α and β (henceforth designated S Q GI^ • GGTase-I is dependent on both Mg 2+ and Zn 2+ for optimal activity. Demonstration of the Zn 2+ dependence required prolonged incubation against, or purification in the presence of, a chelating agent. This property has led to the designation of GGTase-I as a zinc metalloenzyme (Moomaw and Casey, J. Biol. Chem. 267:17438 (1992)) . The properties of GGTase-I are similar to those of a related enzyme, protein farnesyltransferase (FTase) . FTase transfers the prenyl moiety from farnesyl diphosphate to the cysteine residue of substrate proteins. FTase protein substrates, like those for GGTase-I, possess a C-terminal CAAX motif. The "X" residue of mammalian FTase substrates, however, is generally methionine, serine or glutamine as opposed to leucine for GGTase-I substrates (Moores et al, J. Biol. Chem. 136:14603 (1991) ; Moomaw and Casey, J. Biol. Chem. 267:17438 (1992)) . Substrates for FTase include p21 ras protein, lamin B and several proteins involved in visual signal transduction (Clarke, Ann. Rev. Biochem. 61:355 (1992)) . Like GGTase-I, FTase is dependent upon Mg 2+ and Zn + ions for optimal activity (Reiss et al, J. Biol. Chem. 267:6403 (1992)) . Purified mammalian FTase is composed of two nonidentical subunits, α and β (henceforth designed βF) , with apparent molecular masses of approximately 48 kDa and 46 kDa, respectively, on SDS-PAGE (Reiss et al, Cell 62:81 (1990)) . cDNA clones encoding the FTase α and βF subunits have been isolated and their deduced amino acid sequences are homologous to the Saccharamoyces cerevisiae proteins Ram2 and Dprl/Raml, respectively, which encode the subunits of yeast FTase (Moores et al, J. Biol. Chem. 136:14603 (1991) ; Chen et al, Proc. Natl. Acad. Sci. USA 88:11368 (1991) ; Kohl et al, J. Biol. Chem. 266:18884 (1991) ; He et al, Proc. Natl. Acad. Sci. USA 88:11373 (1991)) . The 48 kDa α subunits of mammalian GGTase-I and FTase have been shown to be immunologically crossreactive, suggesting that these two enzymes share a common α subunit (Moomaw and Casey, J. Biol. Chem. 267:17438 (1992) ; Kohl et al, J. Biol. Chem. 266:18884 (1991) ; Seabra et al, Cell 65:429 (1991)) . Similarly, a mutation in the S. cerevisiae gene RAM2, which encodes the α-like subunit of yeast FTase, results in a strain with defects in both GGTase-I activity and FTase activity (Moores et al, J. Biol. Chem. 136:14603 (1991) ; Kohl et al, J. Biol. Chem. 266:18884 (1991)) . Further confirmation of a common subunit for yeast FTase and GGTase-I came from the bacterial coexpression of Ram2 with Raml that resulted in FTase activity (He et al, Proc. Natl. Acad. Sci. USA 88:11373 (1991)), while coexpression of Ram2 with Cdc43/Call resulted in GGTase- I activity (Mayer et al, J. Biol. Chem. 267:20589 (1992)) . Since the S. cerevisiae Cdc43/Call subunit of GGTase-I shows amino acid similarity to yeast Raml/Dprl and mammalian βF, it may be the yeast homolog of mammalian βggi (Ohya et al, J. Biol. Chem. 266:12356 (1991)) . GGTase-I differs from the related enzyme Rab geranylgeranyltransferase, also called protein geranylgeranyltransferase type II (designated GGTase- II) , which attaches a geranylgeranyl group to the COOH- terminal cysteines in small GTP-binding proteins that terminate in Cys-Cys or Cys-X-Cys motifs (Moores et al, J. Biol. Chem. 136:14603 (1991); Seabra et al, J. Biol. Chem. 267:14497 (1992); Horiuchi et al, J. Biol. Chem. 266:16981 (1991)) . Target proteins of GGTase-II include RablA, which resides in the endoplasmic recticulum and Golgi complex, and Rab3A, a component of synaptic vesicles (Pfeffer, Trends. Cell. Biol. 2:41 (1992)) . GGTase-II does not recognize COOH-terminal peptides corresponding to its target proteins, rather, substrate recognition appears to involve additional determinants on the Rab proteins (Moores et al, J. Biol. Chem. 136:14603 (1991) ; Khosravi-Far et al, J. Biol. Chem. 267:24363 (1992)) . GGTase-II consists of three protein components. One component, the 95 kDa Rab escort protein, appears to bind substrate proteins and presents them to the catalytic subunits of the enzyme (Andres et al, Cell 73:1091 (1993)) . The catalytic component of GGTase-II contains two tightly associated polypeptides with apparent molecular masses of 60 kDa and 38 kDa that, respectively, show similarity to the α and SF subunits of FTase (Armstrong et al, J. Biol. Chem. 268:12221 (1993) ) . The present invention provides nucleic acid sequences encoding GGTase-I, in particular, the & QQ J subunit. These sequences can be used to recombinantly produce GGTase-I. The availability of large quantities of the enzyme permits the production of geranylgeranyl- modified proteins and peptides having diagnostic and therapeutic applications. In addition, the enzyme can be used to screen compounds for the potential to alter GGTase-I activity. Such compounds can be expected to be useful in pharmacological intervention strategies in areas including cancer and inflammation. OBJECTS AND SUMMARY OF THE INVENTION It is a general object of the invention to provide a nucleotide sequence encoding GGTase-I, particularly the β subunit thereof. It is a further object of the invention to provide a method of synthesizing GGTase-I, or the β subunit thereof, and a method of screening compounds for the ability to alter GGTase-I activity. Various other objects and advantages of the present invention will be apparent to those skilled in the art from a reading of the disclosure that follows. In one embodiment, the present invention relates to an isolated nucleic acid encoding GGTase-I. In a further embodiment, the present invention relates to an isolated nucleic acid encoding the β subunit of mammalian GGTase-I, or portion thereof of at least 15 consecutive bases, or complement thereof. The invention also relates to recombinant molecules comprising such nucleic acids and vectors, and to host cells comprising same. In addition, the present invention relates to a method of producing GGTase-I or the β subunit of GGTase-I, or portion thereof, comprising culturing the above-described host cells under conditions such that the nucleic acid is expressed and GGTase-I or the β subunit of GGTase-I, or portion thereof, is thereby produced. In a further embodiment, the present invention relates to an isolated nucleic acid consisting essentially of a double-stranded DNA molecule, one strand of which encodes the β subunit of mammalian GGTase-I, or portion thereof of at least 15 consecutive base pairs. The invention also relates to a recombinant molecule comprising such a nucleic acid operably linked to and in inverse orientation with respect to a promoter. The invention further relates to a method of inhibiting the production of GGTase-I in a host cell comprising introducing into the cell such a recombinant molecule under conditions such that the nucleic acid is transcribed and production of the GGTase-I is thereby inhibited. In yet another embodiment, the present invention relates to a method of screening a test compound for the ability to alter GGTase-I activity. The method comprises comparing the GGTase-I activity of a sample in the presence and absence of the test compound, a reduction in the activity in the presence of the test compound being indicative of inhibitory activity of the test compound and an increase in the activity being indicative of an activating activity of the test compound. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1. Nucleotide (SEQ ID NO:l) and deduced amino acid (SED ID NO:2) sequences of rat GGTase-I & QQ J subunit ( β QGl) • Single letter abbreviations are used for the deduced amino acids. Figure 2. Nucleotide (SEQ ID NO:3) and deduced amino acid (SEQ ID NO:4) sequences of human GGTase-I β QQ subunit. The 3 ' -untranslated sequences and 5'- untranslated sequences are included. Single letter abbreviations are used for the deduced amino acids. Figure 3. Nucleotide sequence of intermediate pRD566 (SEQ ID NO:5), which contains the complete coding sequence for human β Q GI an< ^ which is eventually translationally coupled to the coding sequence for human FPTase-α subunit. Figure 4. Nucleotide sequence of pRD577 (SEQ ID NO:6), which contains the complete coding sequence for human & QQ translationally coupled to the coding sequence for human FPTase-α subunit through a sequence which expresses the Glu-Glu-Phe epitope tag and contains the ribosomal binding site for expression of Q Gl • Figure 5. SDS-PAGE analysis of GGTase-I obtained from Sf9 cell expression. Aliquots of pools obtained from each of the processing steps in the purification on an 11% acrylamide gel. Polypeptides were visualized by Coomassie Blue staining. The arrows indicate the migration positions of molecular weight standards; lane 1, 25 μg of the soluble extract; lane 2, 25 μg of the DEAE pool; lane 3, 1 μg of the Q-HP pool. Figure 6. Protein substrate specificity of purified recombinant GGTase-I. Assays were conducted by standard procedures (Casey et al, Proc. Natl. Acad. Sci. USA 88:8631 (1991); Moomaw and Casey, J. Biol. Chem. 267:17438 (1992)) and each reaction mixture contained the indicated concentration of substrate protein. Symbols used are (D) , ras-CVLL; (♦) , ras-CVLS. DETAILED DESCRIPTION OF THE INVENTION The present invention relates, in general, to a nucleic acid sequence encoding GGTase-I, particularly, the β subunit thereof, or portion of that encoding sequence. The invention further relates to the encoded protein, polypeptide or peptide. The term "portion", as used herein, and as applied to nucleic acid sequences, relates to fragments of at least 15 bases, preferably, at least 30 bases, more preferably, at least 150 bases and, most preferably, at least 300 bases. As applied to proteins, the term "portion" relates to peptides and polypeptides of at least 5 amino acids, preferably,at least 10 amino acids, more preferably, at least 50 amino acids and most preferably, at least 100 amino acids. The invention also relates recombinant molecules comprising the above nucleic acid sequences and to host cells tranformed therewith. In addition, the invention relates to methods of making the protein, polypeptide or peptide encoded in the nucleic acid sequence by culturing the transformed host cells under appropriate conditions. Furthermore, the invention relates to methods of screening compounds for the ability to alter GGTase-I activity. More specifically, the present invention relates to nucleotide sequences that encode the amino acid sequence of mammalian GGTase-I, particularly, the β subunit thereof, or portions thereof as defined above. In particular, the present invention relates to nucleotide sequences that encode the amino acid sequence given in SEQ ID NO:2 or SEQ ID NO:4 (see also Figures 1 and 2), or portions thereof as defined above (the DNA sequence given in SEQ ID NO:l or SEQ ID NO:3, respectively, being only an example of each (see also Figure 1 and Figure 2) ) . Further, nucleotide sequences to which the invention relates include those encoding substantially the same protein as shown in SEQ ID NO:2 or SEQ ID NO:4, including, for example, intraspecies variations thereof, as well as functional equivalents of the sequences shown in SEQ ID NO:2 or SEQ ID NO:4. The invention further relates to nucleotide sequences substantially identical to the sequences shown in SEQ ID NO:l and SEQ ID NO:3. A "substantially identical" sequence is one the complement of which hybridizes to the nucleic acid sequence of SEQ ID NO:l or SEQ ID NO:3 at 42°C in 4 X saline/sodium citrate (SSC) containing 40% formamide and which remains bound when subjected to washing at 42°C with 0.2 X SSC containing 0.1% SDS (note: 20 X SSC = 3 M sodium chloride/0.3 M sodium citrate) . The invention also relates to nucleic acids complementary to those described above. The present invention also relates to a recombinant molecule comprising a nucleotide sequence as described above and to a host cell transformed therewith. Using standard methodologies, well known in the art, a recombinant molecule comprising a vector and a nucleotide sequence encoding GGTase-I (particularly, the β subunit thereof) , or portion thereof as defined above, can be constructed. Vectors suitable for use in the present invention include plasmid and viral vectors. A plasmid vector into which a DNA sequence encoding the α and/or β subunits of a mammalian GGTase are cloned can be any vector compatible with transformation into a selected .host cell, for example, a bacterial cell. Such vectors include, but are not limited to, derivatives of ColEl (such as pBR322, pUC8, pUC9, pUC18, pUC19, and the like) (Yanish-Perron et al, Gene 33:103 (1985)) or P15a (such as pACYC177, pACYC184, and the like) (Chang and Cohen, J. Bacteriology 134:1141 (1978)) . Other vectors suitable for use in the present invention include pGEM4Z, pVL1392 and pCMV. The nucleotide sequence of the invention can be present in the vector operably linked to regulatory elements, for example, a promoter. Suitable promoters include, but are not limited to, the tac promoter (Ammon et al, Gene 25:167 (1983)), lac promoter (Siebenlist et al, Cell 20:269 (1980)) and trp promoter (Bennet et al, J. Mol. Biol 121:113 (1978)) . Such promoters use E. coli RNA polymerase to transcribe DNA into mRNA. In one embodiment of the instant invention, the promoter is the tac promoter found in the plasmid pBTacl (commercially available from Boehringer Mannheim Biochemicals) . Other promoter/RNA polymerase systems suitable for use in the instant invention include RNA bacteriophage promoters and their cognate RNA polymerase. Examples of such systems include the bacteriophage T7 promoter and T7 RNA polymerase (Studier and Moffat, J. Mol. Biol. 189:113 (1986)) . It is expected that the bacteriophage T7 promoter and RNA polymerase will give higher levels of protein expression than the tac promoter. Promoters derived from SP6, SV40, polyhedrin or adenovirus can also be used. When synthesis of GGTase-I is sought, sequences encoding the α and β subunits can be present in the same vector or in separate vectors. In either case, the sequences are, advantageously, transcribed independently. As indicated above, the recombinant molecule of the invention can be constructed so as to be suitable for transforming a host cell . Suitable host cells include prokaryotic cells, such as bacteria, lower eukaryotic cells, such as yeast, and higher eucaryotic cells, such as mammalian cells, and insect cells. The recombinant molecule of the invention can be introduced into appropriate host cells by one skilled in the art using a variety of known methods. The present invention further relates to a method of producing GGTase-I (particularly, the β subunit thereof) , or portions thereof as defined above. The method comprises culturing the above-described transformed host cells under conditions such that the encoding sequence is expressed and the protein thereby produced. The present invention further relates to GGTase-I (eg mammalian GGTase-I) , particularly, the β subunit thereof, substantially free of proteins with which it is normally associated, or portions thereof as defined above. The proteins, polypeptides and peptides of the invention can be produced recombinantly using the nucleic acid sequences as described above, or chemically using known methods. The protein of the invention can be produced alone or as a fusion product, for example, with a protein such as glutathione S-transferase or maltose binding protein. Such fusion product can be produced recombinantly. For example, the coding sequence of the invention (eg the sequence encoding the β subunit of mammalian GGTase-I) can be cloned in frame with a sequence encoding another protein (such as glutatione-S-transferase or maltose binding protein) and the fusion product expressed in an appropriate host cell (see, for example, (Guan et al, Gene 67:21 (1987) ; Maina et al, Gene 74:365 (1988) ; Smith and Johnson, Gene 67:31 (1988) ) . The proteins, polypeptides and peptides of the invention can be used as antigens to generate GGTase-I specific antibodies, particularly, antibodies specific for the β subunit of GGTase-I. Methods of antibody generation are well known in the art. Both monoclonal and polyclonal antibodies are contemplated, as are binding fragments thereof. One skilled in the art will appreciate that such antibodies can be used to selectively identify and isolate the proteins of the invention, eg, the β subunit of GGTase-I. Alternatively, the antibodies can be used in vivo or in vi tro to block activity of the GGTase-I. The present invention also relates to methods of using the proteins of the invention (eg, recombinantly produced GGTase-I) to screen compounds for their ability to alter (eg inhibit) GGTase-I activity, and thus to identify compounds that can serve, for example, as agonists or antagonists. In a typical screening assay, GGTase-I is incubated with geranylgeranyl diphosphate and a GGTase-I substrate (eg a protein or peptide that includes the CAAX motif recognized by GGTase-I) in the presence and absence of a compound the enzyme altering activity (eg the inhibitory potential) of which is to be tested. Incorporation of the geranylgeranyl group into the substrate is then determined. A reduction in enzyme activity (ie, a reduction in incorporation) in the test sample indicates that the test compound is an inhibitor of the enzyme. An increase in enzyme activity in the test sample indicates that the test compound is an activator of the enzyme. Such screening procedures are useful not only for identifying agents for their potential use in pharmacological intervention strategies in such areas as cancer and inflammation but also for distinguishing selectivity of inhibitors between GGTase-I and related enzymes such as FTase. GGTase-I inhibitors include, but are not limited to, compounds having structures that mimic the specific substrates of GGTase-I. Thus, analogs of geranylgeranyl diphosphate might be expected to show specificity of interaction toward GGTase-I but not FTase (Moomaw and Casey, J. Biol. Chem. 267:17438 (1992) ; Moores et al, J. Biol. Chem. 266:14603 (1991)) . Similarly, CAAX- containing peptides in which the C-terminal residue is leucine also interact strongly with GGTase-I but poorly with FTase and such peptides or their analogs (eg peptidomimetics (see, for example, Kohl et al, Science 260:1934 (1993)) can be used as specific inhibitors of GGTase-I (Casey et al, Proc. Natl. Acad. Sci. USA 88:8631 (1991) ; Yokoyama et al, Proc. Natl. Acad. Sci. USA 88:5302 (1991)) . Other potential inhibitors of GGTase-I include chemical compounds (eg chelators) that specifically interact with the zinc atom contained in GGTase-I that is required for enzymatic activity (Moomaw and Casey, J. Biol. Chem. 267:17438 (1992)) . The nucleic acid and amino acid sequences of the invention have diagnostic and therapeutic applications. For example, peptides representing portions of βgGI tnat specifically bind to substrate proteins and block their modification (eg peptides that mimic the active site environment of GGTase-I subunits) by preventing recognition by GGTase-I. GGTase-I activity can also be blocked by reducing or eliminating the expression of β GGI . For example, antisense oligonucleotides complementary to βgGI ttiRNA can be used to selectively diminish or oblate the expression of the protein (see, for example, Calabrietta, Cancer Research 51:4505 (1991) ) . In addition, catalytic RNA molecules ("ribozymes") can be used to selectively cleave the & QQ J mRNA and thereby prevent its translation (see, for example, Sullenger and Cech, Science 262:1566 (1963)) . Inhibition of GGTase-I activity is advantageous in clinical settings in which GGTase-I is abberantly activated (see Ando et al, J. Biol. Chem. 267:25709 (1992) and Heyworth et al, J. Mol. Biol. Cell 4:261 (1993) for discussion of effect of GGTase-I on protein activation) . The present invention also relates to pharmaceutical compositions comprising the proteins, peptides, or nucleic acids of the invention. The invention also relates to compositions comprising compounds selected using the above-described screening protocol. Such compositions include the active agent in combination with a pharmaceutically acceptable carrier. The amount of active agent in the composition can vary with the agent, the patient and the effect sought. Likewise, the dosage regimen will vary depending on the composition and the disease/disorder to be treated. Certain aspects of the invention are described in greater detail in the non-limiting Examples that follow. EXAMPLES Methodologies and reagents used in at least certain of the Examples below are as follows: Molecular biology techniques used include those described by Sambrook et al (Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1990) ) and Saiki et al (Science 239:487 (1988)) . Enzymes were obtained from New England Biolabs (Beverly, Massachusetts) or Boehringer-Mannheim (Indianapolis, Indiana) . cDNA clones were subcloned into pGEM-4Z or pUC18 or pUC19 and sequenced by the dideoxy chain termination method (Sanger et al, Proc. Natl. Acad. Sci. USA 74:5463 (1977)) using universal primers or specific internal primers. All cDNAs and PCR products were sequenced on both strands. [ 32 P] -labelled DNA probes were synthesized using a random primer labeling kit (BRL or Boehringer-Mannheim) and [ 3 P]dNTPs (Amersham) . Total cellular RNA was isolated from tissue by the guanidinium thiocyanate/CsCl centrifugation procedure (Chirgwin et al, Biochem. 18:5294 (1979)) . Poly(A) + RNA was isolated by oligo(dT) -cellulose chromatography (Sambrook et al, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1990)) . Example I Protein Sequence Determination of GGTase-I Approximately 1 nmol of GGTase-I purified from bovine brain using affinity chromatography as described (Moomaw and Casey, J. Biol. Chem. 267:17438 (1992)) was subjected to electrophoresis on a 11% SDS-polyacrylamide gel and transferred to nitrocellulose paper. The nitrocellulose paper was then stained with Ponceau S to localize the subunit polypeptides. The 48 kDa and 43 kDa bands (corresponding to the α and β Q GI polypeptide components, respectively) were excised from the nitrocellulose and sent to Harvard Microchem (Cambridge, Massachusetts) for processing. Briefly, this involved digestion in situ with trypsin, isolation of peptides produced by microbore HPLC, and sequence determination (Aebersold et al, Proc. Natl. Acad. Sci. USA 84:6970 (1987) ) . High-confidence sequences of three α subunit peptides and five β Q Gl subunit peptides clearly resolved by HPLC were obtained. A sequence comparison between the peptides obtained from the 48 kDa α subunit of bovine GGTase-I and corresponding regions of bovine FTase-α as deduced from a cDNA clone (Kohl et al, J. Biol. Chem. 266:18884 (1991)) are shown (Table I) . TABLE I Amino Acid Sequence of GGTase-I α and S Q G! peptides α Peptide Corresponding peptide from Bovine FTase a 1 FQDVYDYFR FQDVYDYFR (aa 46-54) (SEQ ID NO:7) 2 Q VIQEFK QWVIQEFK (aa 157-164) (SEQ ID NO:8) 3 VLVEWLRDPSQELEFIADILTQDAK VLVEWLRDPSQELEFIADILTQDAK (aa 124-148) (SEQ ID NO:9 Location of peptide (aa) β GGI.-. in mammalian βgg open peptide reading frames 1 TIAFFALSGLDMLD 49-62 (SEQ ID NO.10) 2 GSSYLGIPFNPSK 97-109 (SEQ ID NO.ll) 3 IFQYTNFEK 285-293 (SEQ ID NO:12) 4 NYILSTQDR 296-304 (SEQ ID NO:13) 5 DLHQSWK 356-362 (SEQ ID Nθ:14) The purified 48 kDa α subunit and 43kDa S QGI subunits of bovine brain GGTase-I were digested with trypsin and the resulting peptides were purified by HPLC and sequenced. The GGTase-I α subunit peptides are shown compared to peptides deduced from a cDNA encoding the bovine FTase α subunit (Kohl et al, J. Biol. Chem. 266:18884-18888 (1991) ) . Three different peptides from the α subunit of GGTase-I were sequenced and found to be 100% identical to regions of FTase α indicating that both GGTase-I and FTase share a common subunit (see also Example III below) . Example I I Cloning of the Mammalian GGTase-I S Q GI Subunit cDNA Two degenerate oligonucleotide primers [GCTC- GGATCC-C- (A/G)AA- (A/G) TT-NGT- (A/G)TA- (T/C)TG- (A/G)A (SEQ ID NO:15) and GTCG-GAATTC-ACN-AT(A/C/T) -GCN-TT(C/T) - TT(C/T)-GC (SEQ ID NO:16)] were synthesized based on portions of two S Q GI subunit peptide sequences [IFQYTNFEK (antisense oligo) and TIAFFLSGLDMLD respectively] . The polymerase chain reaction (PCR) (Saiki et al, Science 239:487 (1988)) was performed using DNA obtained from a bovine brain cDNA library as template (Vogel et al, Nature 335:90 (1988)) . A 730 bp PCR product was isolated (SEQ ID NO:26) that hybridized to a degenerate oligonucleotide [GTAC-TCTAGA-GGN- AT(A/C/T) -CCN-TT(T/C) -AA(T/C) -CC (SEQ ID NO:17) ] encoding part of the peptide GSSYLGIPFNPSK (peptide 2 in Table I) . The PCR fragment was cleaved with EcoRI and BamHI (restriction sites in the PCR oligos) and cloned into pUC19 creating pRD548. To isolate human cDNAs encoding the S GG subunit, a 300 bp EcoRI-HindiII fragment containing the N-terminal portion of the coding sequence in pRD548 was [ 32 P] - labelled and used to screen approximately 10 6 plaques each from both a human placenta cDNA library in λgtll (Clonetech) and a human kidney cDNA library in λmaxl (Clonetech) as described (Kohl et al, J. Biol. Chem. 266:18884 (1991)) . Six cDNA clones were isolated from the human placenta cDNA library and seven were isolated from the human kidney cDNA library. Phage from the λgtll library were isolated and the cDNA inserts subcloned into pUC18 as EcoRI fragments. cDNA inserts from clones from the λmaxl library were exised as phagemids. A plasmid containing the 1.55 kb cDNA from clone 3 from the human placenta cDNA library was designated pRD550. The insert in pRD550 contains all but the N-terminal 36 codons for S Q GI • τhe phagemid containing the 0.7 kb cDNA from clone 27 from the human kidney cDNA library was designated pRD558. The insert in pRD558 encodes the N-terminal 123 amino acids of S GGI . Construction of a plasmid with the complete human β GGI coding sequence was caried out as follows: PCR was performed on pRD558 placing a BamHI and Seal site upstream of the S GG start codon. This DNA was cleaved with BamHI and Xhol, which cleaves within the S Q GI coding sequence, creating fragment 1 of 0.13 kb. Fragment 2 was a 1.52 kb XhoI-EcoRI fragment from pRD550 that contained the coding sequence downstream of the Xhol site. Fragments 1 and 2 were cloned into BamHI- EcoRI digested pUC18 creating pRD566 which contains the complete coding sequence for human S Q GI and 3 ' - untranslated sequences. The base sequence for pRD566 is shown in Figure 3. To isolate rat cDNAs encoding the β GGj subunit, the PCR probe from pRD548 was labeled and used to screen a rat brain 5" -stretch cDNA λgtlO library (Clontech) . Duplicate filters were hybridized in 4 x SSC (1 x SCC=150mM NaCl/15mM sodium citrate, pH=7) and 40% formamide (Sambrook et al, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1990)) at 42°C with 2xl0 6 cpm of [ 32 P] -labeled probe per ml of hybridization buffer. The filters were washed in 2xSSC, 0.1% SDS twice for 15 min at 42°C and then in 0.2 x SCC, 0.1% SDS for 30 min at 42°C. Of the lxlO 6 plaques that were screened, five positives were identified and plaque purified. The clone with the longest 5 '-end (designated as clone 22) was subcloned into pGEM-4Z and sequenced on both strands. DNA sequencing of the clone indicated that it contains all but the first two codons of the rat & QQ subunit. To isolate the N-terminal coding sequence for rat β GG , the 5'-rapid amplification of cDNA ends (RACE) procedure was used to extend the 5 ' -end of clone 22 (Frohman in PCR Protocols: A Guide to Methods and Applications (Innis et al, eds. ) , pp. 28-38, Academic Press, San Diego (1990)) . Three primers were prepared based on the 5' -end sequences of clone 22. First strand cDNA was synthesized from rat brain mRNA with one of the primers and the cDNA was then tailed with dATP using terminal transferase. Two rounds of PCR reactions were performed using the two nested primers and an oligo dT primer. The RACE products obtained were cloned into pGEM-4Z. Twelve clones from different PCR reactions were sequenced on both strands and all yielded identical sequences. The DNA sequence of these clones contained an in frame ATG codon 3 base pairs upstream of the 5 ' - end of the cDNA in clone 22. This ATG codon is in the same position as the initiation codon found in the cDNA sequence of human β G GI '(Figure 2) . A cDNA encoding the complete rat β Q GI subunit of GGTase-I was obtained by a combination of screening with the 730 bp PCR probe and RACE techniques as described above. The nucleotide sequence of the cDNA encoding the β GGI subunit of rat GGTase-I is shown in SEQ ID NO:l. The cDNA sequence contains an ATG initiation codon and encodes a protein of 377 amino acids that contains all five peptides the sequences of which were obtained from tryptic digestion of the purified S GG ι subunit (see Table I of Example I) . The predicted molecular mass of the cloned rat GGj polypeptide, 42.4 kDa, is very similar to the 43 kDa observed on SDS-PAGE for the β G ι subunit of the enzyme purified from bovine brain (Moomaw and Casey, J. Biol. Chem. 136:14603 (1991)) . An alignment of the amino acid sequences of the rat and human GGTase-I S Q GI subunits, together with other protein prenyltransferase β subunits, was made. These additional β subunits included those for rat FTase (Chen et al, Cell 66:327 (1991)), rat GGTase-II (Armstrong et al, J. Biol. Chem. 268:12221 (1993)) and the CDC43 gene product of S. cerevisiae (Ohya et al, J. Biol. Chem. 266:12356 (1991)) . Only 10 of 377 amino acids differ between rat and human GGTase-I B Q GI subunits, and seven of the ten substitutions involve conservative amino acid changes. In general, the C-terminal regions are more conserved among the protein prenyltransferase β subunits than are the N-terminal regions. Exceptions are the N- terminal regions of the H QQ subunits of rat and human GGTase-I and Cdc43, which show higher homology to one another than to other protein prenyltransferase β subunits. This observation is consistent with the proteins being β subunits of GGTase-I from different species. Example I II Expression and Purification of Recombinant GGTase-I and FTase a) Expression of human GGTase-I in E. coli : To express human GGTase-I in E. coli , the cloned human B Q GI subunit cDNA and the previously cloned human FTase-α subunit cDNA (Omer et al, Biochem. 32:5167 1993)) were coexpressed in a translationally coupled plasmid. In E. coli , the plasmid pT5T-hFPTase-α expresses the human α subunit protein with a C-terminal Glu-Glu-Phe epitope tag from a bacteriophage T7 promoter. The plasmid pT5T-hFPTase-α was obtained as described by Omer et al. (Biochem. 32:5167 (1993)) . Specifically, the coding region of the α subunit of human FPTase was modified by PCR (Saiki et al, Science 239:487 (1988)) such that EcoRI restriction sites were placed immediately upsteam and downstream of the α subunit coding sequence and cloned into pUC18 to create pRD452. The sequence of the insert of pRD452 is as follows: GAATTC-ATG-α codoπs for aa 2 -aa3 7g -TAA-GAAI-r-C- EcoRI M Stop EcoRI (Sacl-Kpnl-Smal-BamHI-Hincll-Pstl-Sphl-Hindlll) pUC18 polylin er pRD452 was cut with Sad, which only cuts in the polylinker region of the plasmid, the ends blunted with T4 DNA polymerase and dNTPs and then recircularized. This plasmid was partially digested with EcoRI, the ends filled in with the Klenow fragment of E. coli DNA polymerase and dNTPs and recircularized. A plasmid from this step, in which the EcoRI site downstream of the coding sequence for the α subunit of human FPTase was filled in, was identified and named pRD494. The sequence of the insert in pRD494 is the following: GAATTC-ATG-αsubunit codons aa 2 -aa 379 -TAA-GAATTAATTC- EcoRI M stop (Kpnl-Smal-BamHI-Hincll-Pstl-Sphl-Hindlll) (SEQ ID NO:18). The Sad restriction endonuclease site in this plasmid was completely lost . Synthetic oligonucleotides encoding an approximately 70bp EcoRI-Banll fragment at the 5 ' -end of the α subunit coding sequence were made that contained primarily A or T at the third position of each codon, and inserted into pRD494 that had been cut with EcoRI and Banll to create pRD493 . The sequence of the α subunit coding sequence and the surrounding restriction sites in pRD493 are as follows : GAATTCTAGATAT-ATG GCT GCT ACT GAA GGT GTT GGT GAA GCT GCA CAG GGT GGT- EcoR1 M A A T E G V G E A A Q G G codons for aa 15 -aa379 of α subunit of FPTase-TAA-GAATTAATTC- stop (Kpnl-Smal-BamHI-Hincll-Pstl-Sphl-Hindlll) (SEQ ID NO:19 and SEQ ID NO.20) The 5' -end of the α subunit coding region of pRD493 was modified by PCR placing a BamHI site along with additional sequences that would facilitate translational coupling of the α subunit to the φlO coat protein. This 0.8 kb BamHI- Spel fragment was ligated with a Spel-Hindlll fragment from pRD471 to BamHI-Hindlll cut pT5T (Eisenberg et al, Nature 343:341 (1990)) creating pT5T-FPTaseα. The sequence of the insert in pT5T-FPTase-α is as follows: BamHI G-GAT-CCA-TTG-GAG-GAT-GAT-TAA ATG GCT GCT ACT GAA GGT GTT GGT GAA GCT GCA CAG GGT GGT D P L E D D stop M A A T E G V G E A A Q G G GAG CCC-α codons aa,--aa- 78 -GAG GAG TTT TAA TTAA GAATTC- Pstl-Smal-BamHI-Sall-Pstl-Hindlll (SEQ ID NO:21 E P E E F stop Pad EcoRI and SEQ ID NO:22) The coding sequence for the human B Q GI protein was cloned downstream of the α subunit coding sequence in pT5T-hFPTase-α as follows. Fragment 1, a 0.5 kb Spel- Xhol fragment, containing the sequence CT between the C- terminus of α and the N-terminus of the β QG I subunit coding sequences was made by recombinant PCR using pT5T- hFPTase-α and pRD566 as templates (Higuchi(1990) in PCR Protocols: A Guide to Methods and Applications (Innis, M.A., Gelfand, D.H., Sninsky, J.J. & White, T.J., eds.) , pp. 177-183, Academic Press, San Diego) . Fragment 2, a 1.52 kb XhoI-EcoRI fragment from pRD566 contained the part of the βQG l coding sequence not in fragment 1. Fragment 3 was a 6.2 kb Spel (partial digestion) -EcoRI fragment from pT5T-hFPTase-α that contained the portion of the α coding sequence not in fragment 1 and the vector and promoter sequences from pT5T-hFPTase-α. Fragments 1, 2 and 3 were ligated together to create pRD577 which has the following structure: RBS pT5T - α coding -GAG-GAG-TTT-TAA-CTT-ATG-GTA- B GG) coding (SEQ ID NO:23) E E F stop The coding sequence for the human β Q GI subunit was translationally coupled to the α subunit coding sequence with the ribosomal binding site (RBS) , for expression of ^GGI' within the Glu-Glu-Phe epitope tag. The base sequence for pRD577 is shown in Figure 3. To express human GGTase-I, pRD577 was transformed into E. coli BL2KDE3), creating strain RD578 (deposited at the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland, and was given accession number ) , grown and induced with 0.5 mM isopropyl-β-D-thiogalactoside as described (Omer et al, Biochemistry 32:5167 (1993)) . Recombinant, human GGTase-I was purified from the cells essentially as described for human FTase using a YL1/2 antibody column, which binds the Glu-Glu-Phe epitope tag on the α subunit, and an optional MonoQ HR 5/5 column (Omer et al, Biochemistry 32:5167 (1993)) . The GGTase-I eluted from the MonoQ column at approximately 0.25 M NaCl. b) Expression of rat GGTase-I in Sf9 cells: The rat β GGj CDNA was subcloned using standard procedures into PVL1392 vector, the resulting plasmid is termed PVL1392-β GG . The entire coding region of the FTase-α subunit cDNA (obtained from ATCC) was also subcloned into PVL1392 (PVL1392-0C) . To generate recombinant baculoviruses, Sf9 cells were transfected with 0.5 μg of wild-type viral DNA (PharMingen) and 2 μg of both PVL1392-β GGI and PVL1392-α. The recombinant viruses obtained were purified by standard procedures (Summers and Smith, Texas Agricultural Experiment Station, Bulletin #1555 (1987)) and used to infect one liter of Sf9 cells at a multiplicity of infection of 5. Cells were harvested at 75 hr post-infection and an extract . prepared. GGTase-I was purified from the soluble fraction of the extract by sequential chromatography on DEAE-Sephacel and Q-HP resins. SDS-PAGE analysis of purified GGTase-I showed the expected composition of subunit polypeptides at ~48 kDa and ~43 kDa (Figure 5) . Anti-peptide antisera were produced to both β GGj. and FT-α. For GGj _/ the synthetic peptide containing the sequence [C] GSSYLGIPFNPSK (SEQ ID NO:24) representing the deduced amino acid sequence from aa97 to aal09 in the GGj cDNA with an appended Cys residue for crosslinking to keyhole limpet hemocyanin (KLH) . For FT-α, the synthetic peptide was IGRSLQSKHSTE [C] (SEQ ID NO:25) representing the deduced amino acid sequence from aa359 to aa371 in the rat FT-α cDNA (Chen et al, Proc. Natl. Acad. Sci. USA 88:11368 (1991)) with an appended Cys residue. Both peptides were coupled to KLH through the cysteine residues and sent to Noble Research, Inc. for immunization of rabbits and sera production. Immunoblotting using the immune sera was performed as previously described (Mu by and Gilman, Meth. Enzymol . 195:215 (1989)) . The antisera raised to the β Q GI peptide specifically recognized the 43 kDa polypeptide in purified recombinant GGTase-I while the antisera raised to the FT-α peptide specifically recognized the 48 kDa polypeptide. Example IV Enzymatic Properties of Recombinant GGTase-I Enzyme activity of human GGTase-I prepared using the YLY2 antibody column was compared to that for human FTase in the use of protein substrates Ras-CVLS or Ras- CAIL and lipid substrates farnesyl diphosphate (FPP) and geranylgeranyl diphosphate (GGPP) (Moores et al, J. Biol. Chem. 136:14603 (1991); Yokoyama et al Proc. Natl. Acad. Sci. USA 88:5302 (1991), Moomow et al J. Biol. Chem. 267:17438 (1992)) . Enzymatic activity of recombinant human GGTase-I FTase GGTase-I Substrates Ras-CVLS + FPP 840 <1 Ras-CAIL + FPP 66 6.6 Ras-CVLS + GGPP 19 <1 Ras-CAIL + GGPP <1 1060 Purified recombinant human GGTase-I and FTase were assayed for activity using the substrates a) Ras-CVLS (ImM) and [ 3 H] FPP (0.5 mM) [Ras-CVLS + FPP] , b) Ras- CAIL (ImM) and [ 3 H] FPP (0.5 mM) [Ras-CAIL + FPP] , c) Ras-CVLS (ImM) and [ 3 H] GGPP (0.5 mM) [Ras-CVLS + GGPP] and d) Ras-CAIL (ImM) and [ 3 H] GGPP [Ras-CAIL + GGPP] as described (Moores et al, J. Biol. Chem. 136:14603 (1991) ) . Briefly, 100 ng of GGTase-I or FTase was incubated in a 300 ml reaction at 30°C and 50 ml aliquots removed after 2, 4, 6, 8 and 10 min and acid/ethanol insoluble radioactivity determined. Each assay was performed in duplicate and the rates of incorporation (nmol-h "1- mg "1 ) were determined and the mean value of the duplicates is shown. The data indicate that the E. coli expressed human GGTase-I enzyme preferentially uses Ras-CAIL and GGPP as substrates in contrast to FTase which preferentially uses Ras-CVLS and FPP as substrates. This is as seen for these two enzymes when isolated from a natural source such as bovine brain (Moores et al, J. Biol Chem. 136:14603 1991, Moomaw and Casey, J. Biol. Chem. 267:17438 (1992)) . The specific activity of the E. coli expressed GGTase-I is similar to the value for GGTase-I purified from bovine brain (490 nmol'h ' ^mg "1 , Moomaw and Casey, J. Biol. Chem. 267:17438 (1992)) . Thus the recombinant, human GGTase-I appears to be similar to enzyme from a natural source. Purified recombinant rat GGTase-I was assayed to determine whether its enzymatic properties were similar to GGTase-I isolated from a natural source. The results of one such experiment are shown (Fig. 6) . The assay conditions and the production of substrate proteins were described (Casey et al, Proc. Natl. Acad. Sci. USA 88:8631 (1991); Moomaw and Casey, J. Biol. Chem. 267:17438 (1992)) . Recombinant GGTase-I can efficiently modify a ras protein containing a leucine residue at the C-terminus (Ras-CVLL) , but not one containing a serine residue (Ras-CVLS) . Ras-CVLS is instead a good substrate for FTase (Casey et al, Proc. Natl. Acad. Sci. USA 88:8631 (1991) ; Reiss et al, Cell 62:81 (1990)) . Additionally, recombinant GGTase-I can specifically recognize short CAAX-type peptides containing a leucine residue at the C-terminus in a fashion indistinguishable from that of the enzyme purified from mammalian tissue (Casey et al, Proc. Natl. Acad. Sci. USA 88:8631 (1991) ) . * * * All documents cited above are hereby incorporated in their entirety by reference. One skilled in the art will appreciate from a reading of this disclosure that various changes in form and detail can be made without departing from the true scope of the invention. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: CASEY, Patrick J. ZHANG, Fang DIEHL, Ronald E. KOHL, Nancy E. OMER, Charles A. (ii) TITLE OF INVENTION: PROTEIN MODIFYING ENZYME (iii) NUMBER OF SEQUENCES: 27 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: NIXON & VANDERHYE P.C. (B) STREET: 1100 NORTH GLEBE ROAD (C) CITY: ARLINGTON (D) STATE: VIRGINIA (E) COUNTRY: U.S.A (F) ZIP: 22201-4714 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentin Release #1.0, Version #1.25 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: PCT/US95/01243 (B) FILING DATE: 31-JAN-1995 (C) CLASSIFICATION: (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: WILSON, MARY J. (B) REGISTRATION NUMBER: 32,955 (C) REFERENCE/DOCKET NUMBER: 1579-92 (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: (703) 816-4000 (B) TELEFAX: (704) 816-4100 (C) TELEX: 200797 NIXN UR (2) INFORMATION FOR SEQ ID NO:l: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1568 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l: GGACAGCGCA TGGCGGCCAC AGAGGATGAC AGACTGGCGG GGAGCGGAGA AGGAGAACGG 60 CTGGATTTCC TGCGGGACCG ACACGTGCGG TTCTTCCAGC GCTGCCTCCA GGTCTTGCCG 120 32 SUBSTITUTE SH BT(RULE26 ) GAGCGGTATT CTTCGCTGGA GACCAGCAGG CTGACAATTG CATTTTTTGC ACTCTCTGGG 180 CTGGATATGT TGGACTCCTT GGATGTGGTG AACAAAGACG ATATAATAGA GTGGATTTAT 240 TCCTTGCAGG TTCTTCCCAC AGAAGACAGG TCAAATCTGG ATCGCTGTGG TTTCCGAGGT 300 TCTTCATATT TGGGTATTCC ATTCAACCCA TCAAAGAATC CAGGCACAGC TCATCCTTAT 360 GACAGTGGAC ACATAGCGAT GACTTACACT GGTCTTTCCT GTTTAATTAT TCTTGGAGAT 420 GATTTAAGCC GAGTAGATAA AGAAGCTTGC TTAGCAGGCT TGAGAGCACT TCAGCTGGAA 480 GATGGGAGCT TCTGTGCTGT TCCTGAAGGC AGTGAGAATG ACATGAGGTT TGTGTACTGT 540 GCTTCCTGCA TTTGCTATAT GCTCAACAAC TGGTCAGGCA TGGATATGAA GAAAGCCATC 600 AGCTACATTA GAAGAAGTAT GTCCTATGAC AATGGCCTGG CACAGGGGGC AGGACTTGAG 660 TCTCATGGAG GATCCACCTT TTGTGGCATT GCGTCACTGT GCCTGATGGG TAAACTGGAA 720 GAAGTTTTTT CAGAGAAAGA ACTGAACCGG ATAAAGAGGT GGTGCATAAT GAGGCAGCAG 780 AACGGGTACC ACGGAAGACC TAACAAGCCT GTCGACACCT GTTACTCTTT CTGGGTGGGA 840 GCAACACTAA AGCTTTTGAA AATTTTCCAG TACACTAACT TTGAGAAGAA TAGGAATTAC 900 ATCTTATCAA CTCAGGATCG CCTTGTTGGG GGATTTGCTA AATGGCCAGA CAGTCATCCA 960 GATGCTTTGC ATGCGTACTT CGGGATCTGT GGCCTGTCAC TAATGGAGGA GAGTGGAATT 1020 TGTAAAGTTC ATCCTGCTCT GAATGTAAGC ACACGAACTT CTGAGCGCCT CCGAGATCTC 1080 CATCAAAGCT GGAAGACCAA GGACTCTAAA CAGTGCTCAG ACAATGTCCA TATTTCCAGT 1140 TGACTAACCC TGGGGTAAAG GGTGTGTAGC ATACGTGTAG CTCAAGGTTA AAAGCCATGT 1200 GTAACCAAGT GTGCTCTTCT TTAAGGGTTA GTCGTAAAAG TCAGAAGCGT GTACTGCTAG 1260 TTCTTCAGGA TATGCTCTTA GGCCAGTGAC CACTGTCATG GATTTCAAGA AAATCCTTGT 1320 TGACGTGTGG ACATCAGCAG AACTCTGGTA TGGTTCTTAA CTGTTACACT GTGTTTCTGA 1380 GACCTTTCAT GGGGCAGATA TGTTTGTAGG TTATCTTCTT AAAACCCTCA GTACAAGTTC 1440 TGGCTTACAA AATGTACGTA AACCTTCAAA ACAAGTTTAC ACTCCATATG GCATTGATAA 1500 TCTTCAGGTG AGCATTTAAC GATCACTTAA AAATCGCTAC TGCTGATGGG AAGAAATTTG 1560 TTTATCCG 1568 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 377 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: Met Ala Ala Thr Glu Asp Asp Arg Leu Ala Gly Ser Gly Glu Gly Glu 1 5 10 15 Arg Leu Asp Phe Leu Arg Asp Arg His Val Arg Phe Phe Gin Arg Cys 20 25 30 Leu Gin Val Leu Pro Glu Arg Tyr Ser Ser Leu Glu Thr Ser Arg Leu 35 40 45 Thr lie Ala Phe Phe Ala Leu Ser Gly Leu Asp Met Leu Asp Ser Leu 50 55 60 Asp Val Val Asn Lys Asp Asp lie lie Glu Trp lie Tyr Ser Leu Gin 65 70 75 80 Val Leu Pro Thr Glu Asp Arg Ser Asn Leu Asp Arg Cys Gly Phe Arg 85 90 95 Gly Ser Ser Tyr Leu Gly lie Pro Phe Asn Pro Ser Lys Asn Pro Gly 100 105 110 Thr Ala His Pro Tyr Asp Ser Gly His lie Ala Met Thr Tyr Thr Gly 115 120 125 Leu Ser Cys Leu lie lie Leu Gly Asp Asp Leu Ser Arg Val Asp Lys 130 135 140 Glu Ala Cys Leu Ala Gly Leu Arg Ala Leu Gin Leu Glu Asp Gly Ser 145 150 155 160 Phe Cys Ala Val Pro Glu Gly Ser Glu Asn Asp Met Arg Phe Val Tyr 165 170 175 Cys Ala Ser Cys lie Cys Tyr Met Leu Asn Asn Trp Ser Gly Met Asp 180 185 190 Met Lys Lys Ala lie Ser Tyr lie Arg Arg Ser Met Ser Tyr Asp Asn 195 200 205 Gly Leu Ala Gin Gly Ala Gly Leu Glu Ser His Gly Gly Ser Thr Phe 210 215 220 Cys Gly lie Ala Ser Leu Cys Leu Met Gly Lys Leu Glu Glu Val Phe 225 230 235 240 Ser Glu Lys Glu Leu Asn Arg lie Lys Arg Trp Cys lie Met Arg Gin 245 250 255 Gin Asn Gly Tyr His Gly Arg Pro Asn Lys Pro Val Asp Thr Cys Tyr 260 265 270 Ser Phe Trp Val Gly Ala Thr Leu Lys Leu Leu Lys lie Phe Gin Tyr 275 280 285 Thr Asn Phe Glu Lys Asn Arg Asn Tyr lie Leu Ser Thr Gin Asp Arg 290 295 300 Leu Val Gly Gly Phe Ala Lys Trp Pro Asp Ser His Pro Asp Ala Leu 305 310 315 320 His Ala Tyr Phe Gly lie Cys Gly Leu Ser Leu Met Glu Glu Ser Gly 325 330 335 lie Cys Lys Val His Pro Ala Leu Asn Val Ser Thr Arg Thr Ser Glu 340 345 350 Arg Leu Arg Asp Leu His Gin Ser Trp Lys Thr Lys Asp Ser Lys Gin 355 360 365 Cys Ser Asp Asn Val His lie Ser Ser 370 375 (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1969 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: GAATAAAATG AACAATTCAG TTCCTCAGTC ACATGAGCTG TGTGTCAAAT GCACAACAGC 60 CGTATGTGGC TCGTGGCCCC TGTACCGGAC ACTCCCATCC CTGCAGAGTT ACTGGACAGT 120 GCTGATCTAG GGATTCTGTT ACAAAATCCA TGAAAGTGTT CAGCACAATG CCGGGCCCAT 180 ATAAACGTCA GTAGTTGTTG TTATTATAAT TAGTCTTGAC CCAACGGCAA ATTCACTTTG 240 AGACCTTAGA TAAATCACTC TACCTCTCTG AGCCTGGTTT CCTTGCCCTA AAAGGATGGC 300 AAGGGGCTGG GCATGGTGGC CACTGAGGAT GAGAGGCTAG CAGGGAGCGG TGAGGGAGAG 360 CGGCTGGATT TCTTACGGGA TCGGCACGTG CGATTTTTCC AGCGCTGCCT CCAGGTTTTG 420 CCGGAGCGCT ATTCTTCACT CGAGACAAGC AGGTTGACAA TTGCATTTTT TGCACTCTCC 480 GGGCTGGATA TGTTGGATTC CTTAGATGTG GTGAACAAAG ATGATATAAT AGAGTGGATT 540 TATTCCCTGC AGGTCCTTCC CACAGAAGAC AGATCAAATC TAAATCGCTG TGGTTTCCGA 600 GGCTCTTCAT ACCTGGGTAT TCCGTTCAAT CCATCAAAGG CTCCTGGAAC AGCTCATCCT 660 TATGATAGTG GCCACATTGC AATGACCTAC ACTGGCCTCT CATGCTTAGT TATTCTTGGA 720 GACGACTTAA GCCGAGTAAA TAAAGAAGCT TGCTTAGCGG GCTTGAGAGC CCTTCAGCTG 780 GAAGATGGGA GTTTTTGTGC AGTACCTGAA GGCAGTGAAA ATGACATGCG ATTTGTGTAC 840 TGTGCTTCCT GTATTTGCTA TATGCTCAAC AACTGGTCAG GCATGGATAT GAAAAAAGCC 900 ATCACCTATA TTAGAAGGAG TATGTCCTAT GACAATGGAC TGGCACAGGG AGCTGGACTT 960 GAATCTCATG GAGGATCAAC TTTTTGTGGC ATTGCCTCAC TATGTCTGAT GGGTAAACTA 1020 GAAGAAGTTT TTTCAGAAAA AGAATTGAAC AGGATAAAGA GGTGGTGTAT AATGAGGCAA 1080 CAAAATGGTT ATCATGGAAG ACCTAATAAG CCTGTAGACA CCTGTTATTC TTTTTGGGTG 1140 GGAGCAACTC TGAAGCTTCT AAAAATTTTC CAATACACTA ACTTTGAGAA AAATAGAAAT 1200 TACATCTTAT CAACTCAAGA TCGCCTTGTA GGGGGATTTG CCAAGTGGCC AGACAGTCAT 1260 CCAGATGCTT TGCATGCATA CTTTGGGATC TGTGGCCTGT CACTAATGGA GGAAAGTGGA 1320 ATTTGTAAAG TTCATCCTGC TCTGAATGTA AGCACACGGA CTTCTGAACG CCTTCTAGAT 1380 CTCCATCAAA GCTGGAAAAC CAAGGACTCT AAACAATGCT CAGAGAATGT ACATATCTCC 1440 ACATGACTGA TTTTAGATTG GGAGGGTGGG GGGGATTTGT AGCATAACTG TAGCTCAAGT 1500 TTAAAAGCCA TGTATAACCA AGTGTGCTCT TTTTTTAAAA GGTAGAGTCT TACAATCAAA 1560 TCTCCTGCTG ATTTCACTTT GGGATATGGT CTTGAGCCAG TAATCTTTAT ACTGGGTTTC 1620 AAGAAAATCT TTGTTGAAGT TTGAACCACA ACTTTGTCGT GGTTCTTAAA TGTTTATACT 1680 GTATTTCTAA GAAGTTGTTT GAGGCAAATT AACTGTATGT GTGTAGGTTA TCTTTTTAAA 1740 AACTCTTCAG TGCAAATTGT ATCTTATTAT AAAATGGACA CAAATTTTCA AGTTTACACT 1800 TCATATAGCA TTGATAATCT TCAGGTGAAC ACTTAGTGAT CATTTAAAAA GCTCACTGCT 1860 GATCGTAGAA AATTTGCTTT AATTAATTAA GTATCTGGGA TTATTCTTTG AAAACAGATG 1920 ACCATAATTT TTTTTAAAGA AGAGTGACTT ATTTTGTCTT ATTCTTAAG 1969 (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 377 amino acids (B) TYPE: amino acid (C) -STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: Met Val Ala Thr Glu Asp Glu Arg Leu Ala Gly Ser Gly Glu Gly Glu 1 5 10 15 Arg Leu Asp Phe Leu Arg Asp Arg His Val Arg Phe Phe Gin Arg Cys 20 25 30 Leu Gin Val Leu Pro Glu Arg Tyr Ser Ser Leu Glu Thr Ser Arg Leu 35 40 45 Thr lie Ala Phe Phe Ala Leu Ser Gly Leu Asp Met Leu Asp Ser Leu 50 55 60 Asp Val Val Asn Lys Asp Asp lie lie Glu Trp lie Tyr Ser Leu Gin 65 70 75 80 Val Leu Pro Thr Glu Asp Arg Ser Asn Leu Asn Arg Cys Gly Phe Arg 85 90 95 Gly Ser Ser Tyr Leu Gly lie Pro Phe Asn Pro Ser Lys Ala Pro Gly 100 105 110 Thr Ala His Pro Tyr Asp Ser Gly His lie Ala Met Thr Tyr Thr Gly 115 120 125 Leu Ser Cys Leu Val lie Leu Gly Asp Asp Leu Ser Arg Val Asn Lys 130 135 140 Glu Ala Cys Leu Ala Gly Leu Arg Ala Leu Gin Leu Glu Asp Gly Ser 145 150 155 160 Phe Cys Ala Val Pro Glu Gly Ser Glu Asn Asp Met Arg Phe Val Tyr 165 170 175 Cys Ala Ser Cys lie Cys Tyr Met Leu Asn Asn Trp Ser Gly Met Asp 180 185 190 Met Lys Lys Ala lie Thr Tyr lie Arg Arg Ser Met Ser Tyr Asp Asn 195 200 205 Gly Leu Ala Gin Gly Ala Gly Leu Glu Ser His Gly Gly Ser Thr Phe 210 215 220 Cys Gly lie Ala Ser Leu Cys Leu Met Gly Lys Leu Glu Glu Val Phe 225 230 235 240 Ser Glu Lys Glu Leu Asn Arg lie Lys Arg Trp Cys lie Met Arg Gin 245 250 255 Gin Asn Gly Tyr His Gly Arg Pro Asn Lys Pro Val Asp Thr Cys Tyr 260 265 270 Ser Phe Trp Val Gly Ala Thr Leu Lys Leu Leu Lys lie Phe Gin Tyr 275 280 285 Thr Asn Phe Glu Lys Asn Arg Asn Tyr lie Leu Ser Thr Gin Asp Arg 290 295 300 Leu Val Gly Gly Phe Ala Lys Trp Pro Asp Ser His Pro Asp Ala Leu 305 310 315 320 His Ala Tyr Phe Gly lie Cys Gly Leu Ser Leu Met Glu Glu Ser Gly 325 330 335 lie Cys Lys Val His Pro Ala Leu Asn Val Ser Thr Arg Thr Ser Glu 340 345 350 Arg Leu Leu Asp Leu His Gin Ser Trp Lys Thr Lys Asp Ser Lys Gin 355 360 365 Cys Ser Glu Asn Val His lie Ser Thr 370 375 (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1670 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear ( ii ) MOLECULE TYPE : DNA (genomic ) (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5: GGATCCAGTA CTTATGGTAG CCACTGAGGA TGAGAGGCTA GCAGGGAGCG GTGAGGGAGA 60 GCGGCTGGAT TTCTTACGGG ATCGGCACGT GCGATTTTTC CAGCGCTGCC TCCAGGTTTT 120 GCCGGAGCGC TATTCTTCAC TCGAGACAAG CAGGTTGACA ATTGCATTTT TTGCACTCTC 180 CGGGCTGGAT ATGTTGGATT CCTTAGATGT GGTGAACAAA GATGATATAA TAGAGTGGAT 240 TTATTCCCTG CAGGTCCTTC CCACAGAAGA CAGATCAAAT CTAAATCGCT GTGGTTTCCG 300 AGGCTCTTCA TACCTGGGTA TTCCGTTCAA TCCATCAAAG GCTCCTGGAA CAGCTCATCC 360 TTATGATAGT GGCCACATTG CAATGACCTA CACTGGCCTC TCATGCTTAG TTATTCTTGG 420 AGACGACTTA AGCCGAGTAA ATAAAGAAGC TTGCTTAGCG GGCTTGAGAG CCCTTCAGCT 480 GGAAGATGGG AGTTTTTGTG CAGTACCTGA AGGCAGTGAA AATGACATGC GATTTGTGTA 540 CTGTGCTTCC TGTATTTGCT ATATGCTCAA CAACTGGTCA GGCATGGATA TGAAAAAAGC 600 CATCACCTAT ATTAGAAGGA GTATGTCCTA TGACAATGGA CTGGCACAGG GAGCTGGACT 660 TGAATCTCAT GGAGGATCAA CTTTTTGTGG CATTGCCTCA CTATGTCTGA TGGGTAAACT 720 AGAAGAAGTT TTTTCAGAAA AAGAATTGAA CAGGATAAAG AGGTGGTGTA TAATGAGGCA 780 ACAAAATGGT TATCATGGAA GACCTAATAA GCCTGTAGAC ACCTGTTATT CTTTTTGGGT 840 GGGAGCAACT CTGAAGCTTC TAAAAATTTT CCAATACACT AACTTTGAGA AAAATAGAAA 900 TTACATCTTA TCAACTCAAG ATCGCCTTGT AGGGGGATTT GCCAAGTGGC CAGACAGTCA 960 TCCAGATGCT TTGCATGCAT ACTTTGGGAT CTGTGGCCTG TCACTAATGG AGGAAAGTGG 1020 AATTTGTAAA GTTCATCCTG CTCTGAATGT AAGCACACGG ACTTCTGAAC GCCTTCTAGA 1080 TCTCCATCAA AGCTGGAAAA CCAAGGACTC TAAACAATGC TCAGAGAATG TACATATCTC 1140 CACATGACTG ATTTTAGATT GGGAGGGTGG GGGGGATTTG TAGCATAACT GTAGCTCAAG 1200 TTTAAAAGCC ATGTATAACC AAGTGTGCTC TTTTTTTAAA AGGTAGAGTC TTACAATCAA 1260 ATCTCCTGCT GATTTCACTT TGGGATATGG TCTTGAGCCA GTAATCTTTA TACTGGGTTT 1320 CAAGAAAATC TTTGTTGAAG TTTGAACCAC AACTTTGTCG TGGTTCTTAA ATGTTTATAC 1380 TGTATTTCTA AGAAGTTGTT TGAGGCAAAT TAACTGTATG TGTGTAGGTT ATCTTTTTAA 1440 AAACTCTTCA GTGCAAATTG TATCTTATTA TAAAATGGAC ACAAATTTTC AAGTTTACAC 1500 TTCATATAGC ATTGATAATC TTCAGGTGAA CACTTAGTGA TCATTTAAAA AGCTCACTGC 1560 TGATCGTAGA AAATTTGCTT TAATTAATTA AGTATCTGGG ATTATTCTTT GAAAACAGAT 1620 GACCATAATT TTTTTTAAAG AAGAGTGACT TATTTTGTCT TATTCTTAAG 1670 (2) INFORMATION FOR SEQ ID NO:6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2913 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: GGATCCATTG GAGGATGATT AAATGGCTGC TACTGAAGGT GTTGGTGAAG CTGCACAGGG 60 TGGTGAGCCC GGGCAGCCGG CGCAACCCCC GCCCCAGCCG CACCCACCGC CGCCCCAGCA 120 GCAGCACAAG GAAGAGATGG CGGCCGAGGC TGGGGAAGCC GTGGCGTCCC CCATGGACGA 180 CGGGTTTGTG AGCCTGGACT CGCCCTCCTA TGTCCTGTAC AGGGACAGAG CAGAATGGGC 240 TGATATAGAT CCGGTGCCGC AGAATGATGG CCCCAATCCC GTGGTCCAGA TCATTTATAG 300 TGACAAATTT AGAGATGTTT ATGATTACTT CCGAGCTGTC CTGCAGCGTG ATGAAAGAAG 360 TGAACGAGCT TTTAAGCTAA CCCGGGATGC TATTGAGTTA AATGCAGCCA ATTATACAGT 420 GTGGCATTTC CGGAGAGTTC TTTTGAAGTC ACTTCAGAAG GATCTACATG AGGAAATGAA 480 CTACATCACT GCAATAATTG AGGAGCAGCC CAAAAACTAT CAAGTTTGGC ATCATAGGCG 540 AGTATTAGTG GAATGGCTAA GAGATCCATC TCAGGAGCTT GAATTTATTG CTGATATTCT 600 TAATCAGGAT GCAAAGAATT ATCATGCCTG GCAGCATCGA CAATGGGTTA TTCAGGAATT 660 TAAACTTTGG GATAATGAGC TGCAGTATGT GGACCAACTT CTGAAAGAGG ATGTGAGAAA 720 TAACTCTGTC TGGAACCAAA GATACTTCGT TATTTCTAAC ACCACTGGCT ACAATGATCG 780 TGCTGTATTG GAGAGAGAAG TCCAATACAC TCTGGAAATG ATTAAACTAG TACCACATAA 840 TGAAAGTGCA TGGAACTATT TGAAAGGGAT TTTGCAGGAT CGTGGTCTTT CCAAATATCC 900 TAATCTGTTA AATCAATTAC TTGATTTACA ACCAAGTCAT AGTTCCCCCT ACCTAATTGC 960 CTTTCTTGTG GATATCTATG AAGACATGCT AGAAAATCAG TGTGACAATA AGGAAGACAT 1020 TCTTAATAAA GCATTAGAGT TATGTGAAAT CCTAGCTAAA GAAAAGGACA CTATAAGAAA 1080 GGAATATTGG AGATACATTG GAAGATCCCT TCAAAGCAAA CACAGCACAG AAAATGACTC 1140 ACCAACAAAT GTACAGCAAT AAGAATTAAT TCGGTACCCG GGGATCCTCT AGAGTCGAGG 1200 AGTTTTAAAC TTATGGTAGC CACTGAGGAT GAGAGGCTAG CAGGGAGCGG TGAGGGAGAG 1260 CGGCTGGATT TCTTACGGGA TCGGCACGTG CGATTTTTCC AGCGCTGCCT CCAGGTTTTG 1320 CCGGAGCGCT ATTCTTCACT CGAGACAAGC AGGTTGACAA TTGCATTTTT TGCACTCTCC 1380 GGGCTGGATA TGTTGGATTC CTTAGATGTG GTGAACAAAG ATGATATAAT AGAGTGGATT 1440 TATTCCCTGC AGGTCCTTCC CACAGAAGAC AGATCAAATC TAAATCGCTG TGGTTTCCGA 1500 GGCTCTTCAT ACCTGGGTAT TCCGTTCAAT CCATCAAAGG CTCCTGGAAC AGCTCATCCT 1560 TATGATAGTG GCCACATTGC AATGACCTAC ACTGGCCTCT CATGCTTAGT TATTCTTGGA 1620 GACGACTTAA GCCGAGTAAA TAAAGAAGCT TGCTTAGCGG GCTTGAGAGC CCTTCAGCTG 1680 GAAGATGGGA GTTTTTGTGC AGTACCTGAA GGCAGTGAAA ATGACATGCG ATTTGTGTAC 1740 TGTGCTTCCT GTATTTGCTA TATGCTCAAC AACTGGTCAG GCATGGATAT GAAAAAAGCC 1800 ATCACCTATA TTAGAAGGAG TATGTCCTAT GACAATGGAC TGGCACAGGG AGCTGGACTT 1860 GAATCTCATG GAGGATCAAC TTTTTGTGGC ATTGCCTCAC TATGTCTGAT GGGTAAACTA 1920 GAAGAAGTTT TTTCAGAAAA AGAATTGAAC AGGATAAAGA GGTGGTGTAT AATGAGGCAA 1980 CAAAATGGTT ATCATGGAAG ACCTAATAAG CCTGTAGACA CCTGTTATTC TTTTTGGGTG 2040 GGAGCAACTC TGAAGCTTCT AAAAATTTTC CAATACACTA ACTTTGAGAA AAATAGAAAT 2100 TACATCTTAT CAACTCAAGA TCGCCTTGTA GGGGGATTTG CCAAGTGGCC AGACAGTCAT 2160 CCAGATGCTT TGCATGCATA CTTTGGGATC TGTGGCCTGT CACTAATGGA GGAAAGTGGA 2220 ATTTGTAAAG TTCATCCTGC TCTGAATGTA AGCACACGGA CTTCTGAACG CCTTCTAGAT 2280 CTCCATCAAA GCTGGAAAAC CAAGGACTCT AAACAATGCT CAGAGAATGT ACATATCTCC 2340 ACATGACTGA TTTTAGATTG GGAGGGTGGG GGGGATTTGT AGCATAACTG TAGCTCAAGT 2400 TTAAAAGCCA TGTATAACCA AGTGTGCTCT TTTTTTAAAA GGTAGAGTCT TACAATCAAA 2460 TCTCCTGCTG ATTTCACTTT GGGATATGGT CTTGAGCCAG TAATCTTTAT ACTGGGTTTC 2520 AAGAAAATCT TTGTTGAAGT TTGAACCACA ACTTTGTCGT GGTTCTTAAA TGTTTATACT 2580 GTATTTCTAA GAAGTTGTTT GAGGCAAATT AACTGTATGT GTGTAGGTTA TCTTTTTAAA 2640 AACTCTTCAG TGCAAATTGT ATCTTATTAT AAAATGGACA CAAATTTTCA AGTTTACACT 2700 TCATATAGCA TTGATAATCT TCAGGTGAAC ACTTAGTGAT CATTTAAAAA GCTCACTGCT 2760 GATCGTAGAA AATTTGCTTT AATTAATTAA GTATCTGGGA TTATTCTTTG AAAACAGATG 2820 ACCATAATTT TTTTTAAAGA AGAGTGACTT ATTTTGTCTT ATTCTTAAGG AATTCCTGCA 2880 GCCCGGGGGA TCCGTCGACC TGCAGCCAAG CTT 2913 (2) INFORMATION FOR SEQ ID NO:7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: Phe Gin Asp Val Tyr Asp Tyr Phe Arg 1 5 (2) INFORMATION FOR SEQ ID NO:8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8: Gin Trp Val lie Gin Glu Phe Lys 1 5 (2) INFORMATION FOR SEQ ID NO: 9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: Val Leu Val Glu Trp Leu Arg Asp Pro Ser Gin Glu Leu Glu Phe lie 1 5 10 15 Ala Asp lie Leu Thr Gin Asp Ala Lys 20 25 (2) INFORMATION FOR SEQ ID NO:10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10: Thr lie Ala Phe Phe Ala Leu Ser Gly Leu Asp Met Leu Asp 1 5 10 (2) INFORMATION FOR SEQ ID NO:11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 13 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11: Gly Ser Ser Tyr Leu Gly lie Pro Phe Asn Pro Ser Lys 1 5 10 (2) INFORMATION FOR SEQ ID NO:12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12: lie Phe Gin Tyr Thr Asn Phe Glu Lys 1 5 (2) INFORMATION FOR SEQ ID NO: 13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13; Asn Tyr lie Leu Ser Thr Gin Asp Arg 1 5 (2) INFORMATION FOR SEQ ID NO:14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14: Asp Leu His Gin Ser Trp Lys 1 5 (2) INFORMATION FOR SEQ ID NO:15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 28 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15: GCTCGGATCC CRAARTTNGT RTAYTGRA 28 (2) INFORMATION FOR SEQ ID NO:16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16: GTCGGAATTC ACNATHGCNT TYTTYGC 27 (2) INFORMATION FOR SEQ ID NO:17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17: GTACTCTAGA GGNATHCCNT TYAAYCC 27 (2) INFORMATION FOR SEQ ID NO:18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18: GAATTCATGN TAAGAATTAA TTCN 24 (2) INFORMATION FOR SEQ ID NO:19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 70 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19: GAATTCTAGA TATATGGCTG CTACTGAAGG TGTTGGTGAA GCTGCACAGG GTGGTNTAAG 60 AATTAATTCN 70 (2) INFORMATION FOR SEQ ID NO:20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20: Met Ala Ala Thr Glu Gly Val Gly Glu Ala Ala Gin Gly Gly 1 5 10 (2) INFORMATION FOR SEQ ID NO:21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 94 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21: GGATCCATTG GAGGATGATT AAATGGCTGC TACTGAAGGT GTTGGTGAAG CTGCACAGGG 60 TGGTGAGCCC NGAGGAGTTT TAATTAAGAA TTCN 94 (2) INFORMATION FOR SEQ ID NO:22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 6 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22: Asp Pro Leu Glu Asp Asp 1 5 (2) INFORMATION FOR SEQ ID NO:23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23: NGAGGAGTTT TAACTTATGG TAN 23 (2) INFORMATION FOR SEQ ID NO:24: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24: Cys Gly Ser Ser Tyr Leu Gly lie Pro Phe Asn Pro Ser Lys 1 5 10 (2) INFORMATION FOR SEQ ID NO:25: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 13 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25: lie Gly Arg Ser Leu Gin Ser Lys His Ser Thr Glu Cys 1 5 10 (2) INFORMATION FOR SEQ ID NO:26: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 729 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) ( i) SEQUENCE DESCRIPTION: SEQ ID NO:26: ACGATAGCGT TTTTTGCACT CTCCGGGCTG GATATGTTGG ATTCCTTAGA TGTGGTGAAC 60 AAAGATGATA TAATAGAGTG GATTTATTGG GTGCAGGTCC TTCCCACAGA AGACAGATCA 120 AATCTAAATC GCTGTGGTTT CCGAGGCTCT TCATACCTGG GTATTCCGTT CAATCCATCA 180 AAGGCTCCTG GAACAGCTCA TCCTTATGAT AGTGGCCACA TTGCAATGAC CTACACTGGC 240 CTCTCATGCT TAGTTATTCT TGGAGACGAC TTAAGCCGAG TAAATAAAGA AGCTTGCTTA 300 GCGGGCTTGA GAGCCCTTCA GCTGGAAGAT GGGAGTTTTT GTGCAGTACC TGAAGGCAGT 360 GAAAATGACA TGCGATTTGT GTACTGTGCT TCCTGTATTT GCTATATGCT CAACAACTGG 420 TCAGGCATGG ATATGAAAAA GCCATCACCT ATATTAGAAG GAGTATGTCC TATGACAATG 480 GACTGGCACA GGGAGCTGGA CTTGAATCTC ATGGAGGATC AACTTTTTGT GGCATTGCCT 540 CACTATGTCT GATGGGTAAA CTAGAAGAAG TTTTTTCAGA AAAAGAATTG AACAGGATAA 600 AGAGGTGGTG TATAATGAGG CAACAAAATG GTTATCATGG AAGACCTAAT AAGCCTGTAG 660 ACACCTGTTA TTCTTTTTGG GTGGGAGCAA CTCTGAAGCT TCTAAAAATT TTCCAATACA 720 CCAACTTCG 729 (2) INFORMATION FOR SEQ ID NO:27: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 16 amino acids (B) " TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27: Met Ala Ala Thr Glu Gly Val Gly Glu Ala Ala Gin Gly Gly Glu Pro 1 5 10 15 45A

Claims: WHAT IS CLAIMED IS: 1. An isolated nucleic acid encoding geranylgeranyltransferase type I (GGTase-I) . 2. The nucleic acid according to claim 1 wherein said GGTase-I is mammlian GGTase-I. 3. The nucleic acid according to claim 1 wherein a β subunit of said GGTase-I has the amino acid sequence set forth in SEQ ID NO:2 or SEQ ID NO:4. 4. The nucleic acid according to claim 2 wherein said mammalian GGTase-I is rodent or human GGTase-I. 5. An isolated nucleic acid encoding the β subunit of mammalian GGTase-I, or portion thereof of at least 15 consecutive bases, or complement thereof. 6. The nucleic acid according to claim 5 wherein said mammalian GGTase-I is rodent or human GGTase-I. 7. The isolated nucleic acid according to claim 5 wherein the nucleic acid encodes the amino acid sequence set forth in SEQ ID NO:2 or SEQ ID N0:4, or portion thereof of at least 5 amino acids. 8. The isolated nucleic acid according to claim 7 wherein the nucleic acid has the sequence shown in SEQ ID N0:1 or SEQ ID NO:3, or a sequence 46 substantially identical thereto, or portion thereof of at least 15 consecutive bases. 9. The isolated nucleic acid according to claim 8 wherein said nucleic acid has the sequence shown in SEQ ID NO:l or SEQ ID NO:3, or portion thereof of at least 15 consecutive bases. 10. The isolated nucleic acid according to claim 9 wherein the nucleic acid has the sequence shown in SEQ ID NO: 1 or SEQ ID NO:3. 11. A recombinant molecule comprising said nucleic acid according to claim 1 and a vector. 12. The recombinant molecule according to claim 11 further comprising a promoter operably linked to said nucleic acid sequence. 13. A host cell comprising said recombinant molecule according to claim 11. 14. A method of producing GGTase-I comprising culturing said host cell according to claim 13 under conditions such that said nucleic acid sequence is expressed and said GGTase-I is thereby produced. 15. A GGTase-I produced by the method according to claim 14. 47 16. A recombinant molecule comprising the nucleic acid sequence according to claim 5 and a vector. 17. The recombinant molecule according to claim 16 further comprising a promoter operably linked to said nucleic acid sequence. 18. A host cell comprising said recombinant molecule according to claim 16. 19. A method of producing the β subunit of mammalian GGTase-I, or portion thereof, comprising culturing said host cell according to claim 18 under conditions such that said nucleic acid sequence is expressed and said β subunit of mammalian GGTase-I, or portion thereof, is thereby produced. 20. A β subunit of mammlian GGTase-I produced by the method according to claim 19. 21. An isolated nucleic acid consisting essentially of a double-stranded DNA molecule, one strand of which encodes the β subunit of mammalian GGTase-I, or portion thereof of at least 15 consecutive base pairs. 22. A recombinant molecule comprising the nucleic acid according to claim 21 operably linked to and in inverse orientation with respect to a promoter. 48 23. A host cell comprising the recombinant molecule according to claim 22. 24. A method of inhibiting the production of GGTase-I in a host cell comprising introducing into said cell the recombinant molecule according to claim 22 under conditions such that said nucleic acid is transcribed and production of said GGTase-I is thereby inhibited. 25. A method of screening a test compound for the ability to alter GGTase-I activity comprising: i) reacting a GGTase-I substrate with geranylgeranyl diphosphate and GGTase-I in the presence and in the absence of said test compound; and ii) measuring the transfer of the geranylgeranyl group from geranylgeranyl diphosphate to said substrate, wherein a decrease in the transfer of the geranylgeranyl group to said substrate in the presence of said test compound, relative to the transfer of the geranylgeranyl group to said substrate in the absence of the test compound, is indicative of an inhibitory activity of the test compound, and wherein an increase in the transfer of the geranylgeranyl group to said substrate in the presence of said test compound, relative to the transfer of the geranylgeranyl group to said substrate in the absence of the test compound, is indicative of an activating activity of the test compound. 49

Inventors: CASEY PATRICK J, DIEHL RONALD E, KOHL NANCY E, OMER CHARLES A, ZHANG FANG, CASEY, PATRICK, J., DIEHL, RONALD, E., KOHL, NANCY, E., OMER, CHARLES, A., ZHANG, FANG
Applicants: MERCK & CO INC, UNIV DUKE, DUKE UNIVERSITY, MERCK & CO., INC.
Application year: 1995
Main classification: C12N9
IPC codes: C12N5, C12N9, C12N15, C12Q1, C12R1